Phase II year
2022
(last award dollars: 1696453001)
Phase II Amount
$1,249,997
Neurovation Labs (NL) is revolutionizing brain trauma healthcare for soldiers and civilians. Two of the most significant issues affecting soldier health are Traumatic Brain Injury (TBI) and Post-traumatic Stress Disorder (PTSD), which can occur together. NL is developing the first-ever, reliable biotechnology solution to detect both PTSD and TBI by leveraging a groundbreaking biomarker discovery with patented technology. NL are pioneering an objective, rapid diagnostic brain scan tool able to detect TBI, PTSD, and concurrent PTSD/TBI. The solution can be deployed in urban hospitals or in forward medical stations with minimal equipment. As such, NLs solution represents a clear blue sky strategic opportunity. Having successfully executed a prior Phase II prototype effort, we gained increased interest from USAF stakeholders who remain committed to helping us transition this technology to Phase III. During this proposed Direct to Phase II, NL will continue development of its brain trauma diagnostic tool, will expand its detection capabilities to reliably include TBI, and will adapt it specifically for defense use. To commercialize, NL identified a contract research laboratory partner and multiple pre-clinical research laboratories affiliated with the VA and DoD to perform experiments with future funding (e.g., a Phase III). NLs brain trauma solution may provide great value not just to the warfighter but also to the large suffering civilian population, ending the current epidemic as we know it.
